Truscreen Group Ltd
NZX:TRU
Intrinsic Value
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. [ Read More ]
The intrinsic value of one TRU stock under the Base Case scenario is 0.02 NZD. Compared to the current market price of 0.02 NZD, Truscreen Group Ltd is Overvalued by 15%.
Valuation Backtest
Truscreen Group Ltd
Run backtest to discover the historical profit from buying and selling TRU stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Truscreen Group Ltd
Current Assets | 2.1m |
Cash & Short-Term Investments | 807.2k |
Receivables | 310.4k |
Other Current Assets | 967.9k |
Current Liabilities | 846.3k |
Accounts Payable | 718.5k |
Other Current Liabilities | 127.8k |
Non-Current Liabilities | 39.7k |
Other Non-Current Liabilities | 39.7k |
Earnings Waterfall
Truscreen Group Ltd
Revenue
|
1.9m
NZD
|
Cost of Revenue
|
-1.5m
NZD
|
Gross Profit
|
454.7k
NZD
|
Operating Expenses
|
-2.9m
NZD
|
Operating Income
|
-2.5m
NZD
|
Other Expenses
|
-49.7k
NZD
|
Net Income
|
-2.5m
NZD
|
Free Cash Flow Analysis
Truscreen Group Ltd
TRU Profitability Score
Profitability Due Diligence
Truscreen Group Ltd's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Truscreen Group Ltd's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
TRU Solvency Score
Solvency Due Diligence
Truscreen Group Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Truscreen Group Ltd's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TRU Price Targets Summary
Truscreen Group Ltd
Shareholder Return
TRU Price
Truscreen Group Ltd
Average Annual Return | -24.36% |
Standard Deviation of Annual Returns | 19.63% |
Max Drawdown | -90% |
Market Capitalization | 11.2m NZD |
Shares Outstanding | 560 034 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
Contact
IPO
Employees
Officers
The intrinsic value of one TRU stock under the Base Case scenario is 0.02 NZD.
Compared to the current market price of 0.02 NZD, Truscreen Group Ltd is Overvalued by 15%.